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Prostaglandin endoperoxide synthases (PTGS), commonly referred to as cyclooxygenases (COX-1 and COX-2), catalyze the key step in
the synthesis of biologically active prostaglandins (PGs), the conversion of arachidonic acid (AA) into prostaglandin H2 (PGH2). Although
COX and prostaglandins have been implicated in a wide variety of physiologic processes, an evaluation of the role of prostaglandins in early
mammalian development has been difficult due to the maternal contribution of prostaglandins from the uterus: COX null mouse embryos
develop normally during embryogenesis. Here, we verify that inhibition of COX-1 results in zebrafish gastrulation arrest and shows that
COX-1 expression becomes restricted to the posterior mesoderm during somitogenesis and to posterior mesoderm organs at pharyngula
stage. Inhibition of COX-1 signaling after gastrulation results in defective vascular tube formation and shortened intersomitic vessels in the
posterior body region. These defects are rescued completely by PGE2 treatment or, to a lesser extent, by PGF2a, but not by other
prostaglandins, such as PGI2, TxB2, or PGD2. Functional knockdown of COX-1 using antisense morpholino oligonucleotide translation
interference also results in posterior vessel defect in addition to enlarged posterior nephric duct, phenocopying the defects caused by
inhibition of COX-1 activity. Together, we provide the first evidence that COX-1 signaling is required for development of posterior
mesoderm organs, specifically in the vascular tube formation and posterior nephric duct development.
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Cyclooxygenases (COXs), prostaglandin (PG) endoper-
oxide G/H synthases (PTGS), catalyze the initial step
in the conversion of arachidonic acid to prostaglandins
(PGs) (Supplementary Fig. 1). Although COX-1 and COX-2
are encoded on separate chromosomes, they share similar0012-1606/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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Abbreviations: PG, prostaglandin; COX, prostaglandin endoperoxide
synthase; Indo, indomethacin; PGE2, prostaglandin E2; PGF2a, prostaglan-
din F2a; WT, wild-type.
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1 Co-senior authors.structural and kinetic properties and show distinct expres-
sion and regulation. COX-1 is thought to serve ‘‘house-
keeping’’ functions as a constitutive enzyme, while COX-2
is highly inducible by diverse stimuli including cytokine,
mitogen, growth factor, and tumor promoters. PGs are
important in a wide variety of normal physiologic and
pathologic processes (Smith et al., 2000).
Prostaglandin biosynthetic pathway is initiated by con-
version of arachidonic acid into PGH2 by the enzymatic
action of cyclooxygenases. COX enzymes are inserted in the
ER and nuclear membrane with the substrate-binding pocket
precisely orientated to take up released arachidonic acid
(Smith et al., 2000). The crystal structures of COX-1 and
COX-2 are remarkably similar, with one notable amino acid82 (2005) 274 – 283YDBIO-01940; No. of pages: 10; 4C: 3, 4, 5, 6, 7, 8, 9
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access in COX-2. PGH2 is subsequently converted to one of
several structurally related prostaglandins, including PGE2,
PGD2, PGF2a, PGI2, and thromboxane A2 (TxA2), by the
activity of specific PG synthases. The coupling of PGH2
synthesis to metabolism by downstream enzymes is intri-
cately orchestrated in a cell-specific fashion. Thromboxane
synthase is found in platelets and macrophages, prostacyclin
synthase is found in endothelial cells, and PGF synthase in
uterus, and two types of PGD synthase are found in brain and
mast cells. Two PGE synthases, microsomal PGE synthase
(mPGES), a member of the MAPEG (membrane-associated
proteins in eicosanoid and glutathione metabolism) family,
and cytosolic PGE synthase (cPGES), are responsible for
PGE2 synthesis (Jakobsson et al., 1999).
Understanding the developmental role of cyclooxyge-
nases and the downstream signaling molecules did not
reveal much insight into embryonic role for prostaglandins.
COX-1 homozygous mutant mice did not reveal much
pathology, which was surprising given its ‘‘housekeeping’’
function. COX-2/ mice exhibit multiple defects in
reproduction that include ovulation, fertilization, implanta-
tion, and decidualization, but did not exhibit overt abnor-
malities during embryonic development (Langenbach et al.,
1995; Loftin et al., 2002; Morham et al., 1995). Sub-
sequently, EP receptors and various prostaglandin synthases
were knocked out in mice, but none of the mutants revealed
phenotype during embryonic development (Kobayashi and
Narumiya, 2002). From these studies, it was hypothesized
that either fetal or maternal production of prostaglandins
allows normal development of embryos in the uterus.
Recently, both COX isoforms were isolated in zebrafish
and shown to be genetically and functionally equivalent to
their mammalian orthologs (Grosser et al., 2002). In this
study, knockdown of COX-1, using antisense oligonucleo-
tides morpholino, resulted in gastrulation arrest, while
knockdown of COX-2 failed to produce any phenotype.
Zebrafish is an attractive model for many reasons (Ama-
truda et al., 2002). Each mating gives rise to hundreds of
embryos for study; embryogenesis can be visualized due to
the transparency of the developing embryos; molecular
markers are available for virtually all the tissues; and most
importantly for prostaglandin biology, embryogenesis
occurs outside of mother’s body. Therefore, we sought to
explore the specific role of COX-1 during zebrafish
embryogenesis after the gastrulation period.Materials and methods
Zebrafish maintenance, embryo generation, and staging
AB* and TL WT zebrafish strains were maintained as
described (Solnica-Krezel et al., 1996). Embryos were
obtained from natural spawnings and staged according to
morphology as described (Kimmel et al., 1995).In situ hybridization and antibody staining
Antisense probes for zebrafish cox1 and cox2 were
synthesized as described (Grosser et al., 2002). Antisense
RNA probes were synthesized from cDNAs encoding fli1
(Krauss et al., 1993), flk-1, and pax2.1 (Krauss et al.,
1991). Whole mount in situ hybridization was performed
according to Marlow et al. (2002). All images were
captured with Nikon Coolpix 4500. Each in situ experi-
ment was done at least twice, and approximately 20
embryos were used in each experiment. The primary
antibody was a monoclonal mouse anti-vinculin and the
secondary antibody was a CY2 anti-mouse IgG (Jackson
Immuno). Images were acquired using the Zeiss LSM 510
laser scanning inverted microscope.
Morpholino design and RNA injections
Morpholino design and RNA injections were performed
at the one-cell stage as described (Marlow et al., 2002).
Morpholino antisense oligonucleotide was designed to the
predicted start codon of cox1 (underline indicates the
predicted start codon): cox1-MO (5V-TCAGCAAAAAGT-
TACACTCTCTCAT-3V) as described (Grosser et al., 2002).
Mismatch morpholino against cox1 was also designed to the
predicted start codon of cox1 (underline indicated the
predicted start codon and italic letters indicates mismatched
resides): (5V-TCAcCAtAAAcTTACACTgTCTgAT-3V). Both
morpholinos were obtained from Gene Tools, LLC (Phil-
omath, OR). Zebrafish cox1 sense-capped RNA was
synthesized using mMessage Machine (Ambion, Austin,
TX) after template linearization. For phenotype rescue and
phenocopy experiments, 40–100 pg cox1 RNA and 4–10
ng cox1-MO were used per embryo.
NSAID pharmacology
To inhibit COX activity, embryos were treated with
indomethacin, a non-selective cyclooxygenase inhibitor.
Embryos were incubated overnight at 28-C in 24-well
dishes. Indomethacin (Cayman), celecoxib (Pfizer), and NS-
398 (Cayman) were incubated in embryo medium (EM)
with 1% DMSO. Treatment of embryos at 2–8 cell stage
with 50 AM indomethacin results in gastrulation arrest
phenotype. We treated embryos with 40 AM indomethacin at
tailbud stage or early somitogenesis stage to observe
posterior vessel defect. Celecoxib was used in dose ranging
from 1 AM to 150 AM and NS-398 was used at dose ranging
from 1 AM to 150 AM. Both were treated starting at tailbud
stage.
Prostaglandin assays
Endogenous levels of prostanoids were measured.
Embryos were isolated at 80% epiboly stage and 24 hpf.
The PG content (PGE2, PGF2a, PGD2, thromboxane B2
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stable metabolite of PGI2) of developing embryo was then
quantified by utilizing gas chromatography/negative ion
chemical ionization mass spectrometric assays. Each bar
indicates the mean of three independent measurements, with
each group consisting of at least 100 embryos.
Prostaglandin rescue experiment
To rescue indomethacin-mediated phenotypic effects, we
used commercially available prostaglandins (Cayman),
PGE2, PGF2a, PGI2, TxB2, and PGD2. All PGs were in-
cubated alone at concentration ranging from 1 AM to 100
AM, except for carbaprostacyclin, which was tested at 0.1
AM to 100 AM. For rescue experiments, we supplemented
indomethacin (40 AM)-treated embryos with 1–10 AM of
PGs at 1% DMSO egg media. Both indomethacin and PGs
were incubated at tailbud or early somitogenesis stages.Results
Expression of COX-1 during embryogenesis
Cox1 maternal transcripts were distributed ubiquitously
in zebrafish embryos at early cleavage stages and its
expression persists in all cells during cleavage, blastula,
and gastrula stages (Fig. 1A). At the end of the gastrula
period (10.5 h post fertilization, hpf), we observed cox1
expression localizing in the posterior half of the embryo
(Figs. 1B, C). At the 7 somite stage, higher levels of
cox1 expression were detected in the bilateral stripes in
intermediate and lateral plate mesoderm, which give rise
to future mesodermal organs, such as blood vessels and
nephric ducts. These stripes co-localized with theFig. 1. cox1 transcripts localize to posterior mesoderm organs. Whole mount in si
present at shield stage (A) and localize posterior half of the embryos at tailbud stag
with pax2 (H) and fli1 (G) at 7 somite stage, indicating its expression in post
somitogenesis stage, cox1 transcripts strongly stain posterior mesoderm (D). At 24
cox1 is not altered in casanova mutant, deficient in endoderm derivatives (F).
vasculature and arrowhead points to the distal hypochord. Scale bar: 100 Am.endothelial marker, fli1 (Krauss et al., 1993) (Fig. 1G),
and the nephrogenic marker, pax2.1 (Krauss et al., 1991)
(Fig. 1H), indicating that cox1 is expressed in the
posterior region and enriched in both posterior inter-
mediate and lateral plate mesoderm. During the late
segmentation stage, intense expression of cox1 was seen
broadly in the developing posterior body (Fig. 1D), and
eventually became confined to the distal end of the
nephric duct, forming vasculature, hypochord, and poste-
rior end of notochord at the 24 hpf (Fig. 1E). cox1
staining was not significantly altered in casanova mutant
(Fig. 1F), which lacks gut tube and does not express any
molecular markers of endoderm differentiation (Alexander
et al., 1999; Kikuchi et al., 2001). This is consistent with
cox1 being expressed largely in posterior mesoderm.
Therefore, we hypothesized that COX-1 may be an
important regulator of posterior mesoderm development.
Pharmacologic inhibition of COX-1 results in posterior
mesoderm defect
We then tested whether use of cyclooxygenase inhibitors
would lead to early developmental defects, specifically in
posterior mesoderm. Previously, Grosser et al. showed that
indomethacin, a non-selective COX inhibitor, and NS-398, a
selective COX-2 inhibitor, could specifically inhibit the
respective zebrafish enzymes in vitro as well as in vivo
(Grosser et al., 2002). Indomethacin treatment, starting at
the 2–8 cell stage, caused phenotypic defects in a dose-
dependent manner from 25 AM to 50 AM. At the dose of 50
AM, we observed gastrulation arrest at 50% epiboly stage
(Fig. 2A). At 40 AM, embryos completed epiboly and
gastrulation, but, at the end of embryogenesis, they
exhibited a gross disorganization of the posterior meso-
dermal region of the embryo (Figs. 2B, 3, 4). Treatmenttu hybridization of cox1 (A–H) reveals that its transcripts are ubiquitously
e (B–C) from side view (B) and from posterior view (C). cox1 co-localizes
erior intermediate mesoderm and posterior lateral mesoderm. During late
hpf, cox1 can be seen in various mesodermal structures (E). Expression of
Arrow indicates the distal end of pronephric duct, letter v indicates the
Fig. 2. PGE2 and PGF2a can rescue both gastrulation arrest and posterior mesoderm defects induced by indomethacin. Indomethacin treatment results in
gastrulation arrest at 50 AM (A) and posterior mesoderm defects at 40 AM (B, arrow). Supplementing indomethacin with PGE2 or PGF2a can suppress both the
gastrulation arrest (C, E) and posterior mesoderm defects (D). COX-2 inhibitors, NS-398, or celecoxib do not cause any noticeable phenotypic defects up to
150 AM (G). Two independent experiments were performed (n > 80) in indomethacin, celecoxib, and NS-398 treatment groups. In rescue experiments, we
performed three independent experiments (n > 80) in each of the treatment groups.
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posterior mesoderm formation. This area of defective
development in the embryo parallels the location of cox1
expression (Figs. 1D, E).
To test whether this phenotypic defect was mediated
exclusively by COX-1, we incubated the embryos with a
COX-2 selective inhibitor, NS-398. However, even at 150
AM NS-398, we failed to see any difference in the
morphology of treated embryos compared to the untreated
wild-type embryos (Fig. 2G). Furthermore, incubating the
embryos with another COX-2 selective inhibitor, celecoxib,
failed to elicit any observable phenotypic changes even at
doses up to 150 AM (Fig. 2G), while COX-1 selective
inhibitor, SC-560, did result in posterior mesoderm defectsimilar to indomethacin treatment (data not shown). Taken
together, these results indicate that pharmacologic inhibition
of COX-1, but not of COX-2, results in posterior mesoderm
defects.
Specific inhibition of COX-1 by indomethacin
To examine whether the phenotypic changes associated
with indomethacin treatment resulted directly from inhib-
ition of COX-1 enzymatic activity, we tested whether
supplementing treated embryos with prostaglandins could
suppress the indomethacin-mediated defects. We co-
incubated the indomethacin-treated embryos with PGE2,
PGF2a, or PGI2 in separate experiments. We found that
Fig. 3. COX-1 inhibition causes defect in vascular tube formation. Fli1:EGFP transgenic embryos were treated with 40 AM indomethacin at tailbud stage.
Compared to untreated embryos (A, C), indomethacin treatment results in distended posterior vasculature at day 1 (B, arrow). Posterior vasculature cannot
differentiate into dorsal aorta and posterior cardinal vein (B, inset arrow). At day 2, clear distinction between dorsal aorta and caudal vein can be seen in
untreated embryo (C), but a single distended posterior vessel remains in treated embryo (D). In addition, intersomitic vessels are either shortened or absent at
day 1 (B, inset) and results in shortened intersomitic vasculature at day 2 (D). Indomethacin treatment results in distention of posterior vasculature at day 1 (F),
compared to untreated embryos (E). Staining with flk1, an endothelial marker, reveal the significant reduction or absence of venous staining at day 1 in treated
embryos (H), compared to the wild-type (G). While ephB2, arterial marker, staining shows similar staining between wt (I) and treated embryos (J), flt4, vein
marker, staining shows absence of veinous staining, especially in the arterial–venous boundary (L).
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pressed the development of posterior mesodermal defects
(Figs. 2D, F) observed in embryos treated with indome-
thacin alone (Fig. 2B). Co-incubation of indomethacin
and PGE2 (Fig. 2C) or PGF2a (Fig. 2E) can also
effectively rescue gastrulation arrest phenotype. PGE2
treatment rescued the gastrulation arrest at both 1 AM
and 10 AM, while PGF2a could only suppress the
phenotype at 1 AM (Fig. 2G). We found that PGE2 and
PGF2a, in combination, also rescued both posterior
mesoderm defects, while other prostaglandins, carbapros-
tacyclin, PGD2, or TxA2, had no effect (Fig. 2G). It could
be argued that using 40–50 AM dose may produce COX-
independent effects, but the fact that we can rescue the
posterior defects with PGE2 argues against this claim.
Moreover, we demonstrated the actual levels of indome-
thacin in embryonic tissues are significantly lower than
the level of indomethacin in media in which the embryos
were incubated in these experiments (data not shown).Analyses of prostaglandin profiles during zebrafish
development showed that PGE2, PGF2a, and PGI2 are
the major prostanoids present in the embryos during the
gastrulation stage (7 hpf), while TxA2 was found at very
low levels, and PGD2 was virtually undetectable (Supple-
mentary Fig. 2). Together, these results indicate that
COX-1-derived PGE2 and, to a lesser extent, PGF2a play
critical roles in the regulation of gastrulation and posterior
mesoderm development.
Inhibition of COX-1 results in defective vascular tube
formation
To determine what specific posterior mesodermal struc-
tures depend on COX-1-derived prostaglandins, we ana-
lyzed phenotypic defects in embryos treated with 40 AM
indomethacin. We utilized fli1:EGFP fish, a transgenic line
that expresses green fluorescent protein in all blood vessels
under the control of the fli1 promoter (Lawson and
Fig. 4. COX-1-inhibited embryos are unable to form distinct dorsal aorta
and posterior cardinal vein. Cross-section of anterior (A, C) and posterior
trunk (E, G) in untreated embryos displays distinct dorsal aorta and
posterior cardinal vein. Indomethacin-treated embryos do not form two
vascular tubes but display one distended vessel both in anterior (B, D) and
posterior sections (F, H). ant, anterior; post, posterior. All embryos were
sectioned after staining with flk1.
Fig. 5. Inhibition of COX-1 does not cause defect in somite formation or
VEGF production. Vinculin staining, marker for intersomitic boundary,
reveals normal somite formation in the trunk both in control group (A) and
treated group (B). In the tail region, vinculin staining is overlayed on DIC
image of the same area. It also reveals that somite formation of the tail is
unchanged in control group (C) vs. treated group (D). Somites in the treated
embryos produce normal amounts of VEGF (F), compared to the untreated
group (E).
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consists of dorsal aorta that makes a 180- turn at its caudal
end to form the caudal vein. The caudal vein forms a
network veinous plexus that continues into the trunk,
becoming a single distinct posterior cardinal vein (PCV)
(Isogai et al., 2001). Intersegmental vessels sprout and
elongate from the dorsal aorta and posterior cardinal vein to
form dorsal longitudinal vessels (DLV). To our surprise,
indomethacin treatment caused the posterior vasculature to
remain as a single distended vessel at 24 hpf (Fig. 3B inset)
and 48 hpf (Fig. 3D), compared to the untreated embryo
(Figs. 3A inset, C). At day 2, a clear demarcation was seen
between arterial and venous vessels in control embryos (Fig.
3C), whereas indomethacin-treated embryos continued to
exhibit a single vessel, unable to differentiate into distinctarterial and venous system (Fig. 3D). We found that
indomethacin treatment results in distention of the posterior
vasculature at 24 hpf (Fig. 3F). Circulation of blood was
markedly slowed and blood cells were pooled in the
distended vessel. These circulation defects result in
decreased hydrostatic blood pressure and led to pericardial
edema at 48 hpf, and all treated embryos died within the
first 5 days post fertilization.
Inhibition of COX-1 results in reduction of veinous vessel
We then performed in situ hybridization revealing
expression of several blood vessel markers to understand
the specific defects in the vasculature caused by COX-1
interference. Untreated embryos showed continuous flk1
(Fouquet et al., 1997; Liao et al., 1997) staining in the dorsal
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treated embryos show a significant reduction of flk1 staining
in the posterior vasculature (Fig. 3H). The marked reduction
in flk1 staining is clear when compared to untreated embryos
(Fig. 3G). We then examined arterial and venous specific
markers to further understand the defect in vessel formation.
ephB2, a marker specific for artery, showed similar staining
between untreated (Fig. 3I) and treated embryos (Fig. 3J).
However, staining with flt4 (Lawson et al., 2001), a marker
specific for vein, revealed a decrease of posterior cardinal
vein as well as venous plexus found in caudal vein (Fig. 3L),
compared to untreated embryos (Fig. 3K). Most striking
reduction was in the boundary separating arterial and
veinous vessel, which is absent also in the blood vessel of
indomethacin-treated fli1:GFP transgenic (Fig. 3B inset).
Next, we sectioned flk1-stained embryos both treated with
indomethacin and untreated. Cross-sections of anterior and
posterior trunk portion of flk1 embryos revealed that proper
tube formation did not occur in indomethacin-treated
embryos. Anterior (Fig. 4C) and posterior (Fig. 4D) sections
of the untreated embryo show two distinct tube structures,
dorsal aorta (DA) dorsally and posterior cardinal vein (PCV)
ventrally, while inhibition of COX-1 results in defective tube
formation and strong reduction of PCV staining both in the
anterior (Fig. 4G) and posterior (Fig. 4H) sections of the
trunk. These experiments strongly suggest that the indome-
thacin-treated embryos are unable to form separate tubes of
artery and veinous systems, but, instead, form a single,
distended vessel.
To understand the timing requirement of COX-1 function
in vasculogenesis, we varied the starting time of treatment
from the tailbud stage (10 hpf) to 36 hpf and found that
altering the initiation time did not affect the vascular defect
analyzed at 38 hpf (Fig. 5). In addition, we initiated
treatment at the 5 somite stage and discontinued treatment
at various points before 32 hpf. Interestingly, we found that
stopping treatment anytime before 25 somites resulted in the
absence of a posterior vessel defect, indicating that COX-1-
derived prostaglandins are required after 25 somite stage for
posterior vessel formation (Fig. 5). Angioblasts firstFig. 6. COX-1 signaling is required at 25 somite stage for posterior vessel forma
starting indomethacin treatment at various stages. Starting treatment at 20 s, 25 s
treatment at 5 s to any stage before 25 somites resulted in absence of posterior v
posterior vessel defect in 35% and 80% of the embryos respectively. Red line incoalesce to form a single cord at 22 somite stage. Then,
arterial and venous angioblasts undergo morphogenesis and
eventually form distinct domains and align in the form of
rudimentary and distinct tubes beginning at 26 somite stage
(Parker et al., 2004). Based on these results, we hypothesize
that COX-1 may function at this cord-to-tube transition to
regulate proper tube formation. Therefore, inhibition of
COX-1 activity at 24–26 stage mostly likely results in
vascular tube formation.
COX-1 inhibition causes shortened intersomitic vessel
formation
Inhibition of COX-1 activity also causes defect in
intersomitic vessel formation. Intersomitic vessels begin to
grow out of dorsal aorta at around 20 hpf, while the
angioblasts are actively coalescing to form a vascular cord
(Isogai et al., 2003). In Fli1-GFP transgenic embryos,
treatment with indomethacin resulted in shortened or absence
of intersomitic vessel at 24 hpf (Fig. 3B), compared to the
longer intersomitic vessels seen in untreated embryos.
Removing the indomethacin at 24 hpf did not restore the
intersegmental vessel formation at 48 hpf, and 30% of the
intersomitic vessels were still shortened. To understand
whether the shortening of intersomitic vessel is due to a
primary defect in the vessel formation, we examined whether
indomethacin causes defect in somite formation. Since
intersomitic vessels transverse through the boundary between
the myotomes (Isogai et al., 2003), we stained the treated
embryos with vinculin antibody and found that the somite
boundary is largely normal in treated embryos. Somites are
formed correctly in treated embryos, both in the trunk and tail
regions (Figs. 5B, D). In addition, expression of vegf gene,
encoding a key regulator of intersomitic vessel angiogenesis,
in the somites also appeared unaltered in both control and
treated groups (Figs. 5E, F). Therefore, we conclude that
defect in somite formation or VEGF production is not
responsible for shortened intersomitic vessels, suggesting a
direct involvement of COX-1 in intersomitic vessel develop-
ment (Fig. 6).tion. We monitored the presence of posterior vessel defect at 38 hpf after
, 25 hr or 30 hpf to 38 hpf all resulted in posterior vessel defect. Starting
essel defect, whereas ending the treatment at 28 hpf and 32 hpf resulted in
dicates timing of indomethacin treatment.
Y.I. Cha et al. / Developmental Biology 282 (2005) 274–283 281Functional knockdown of COX-1 by knockdown experiment
We next asked whether interference with COX-1 trans-
lation, using antisense morpholino-modified oligonucleo-
tides (MO), mimics the posterior mesoderm defects
of indomethacin treatment. Given that embryos injected
with high doses of MOs halt development at early
gastrulation (Grosser et al., 2002), we injected the
embryos with lower amounts of cox1-MO that allowed
them to progress past gastrulation. Interestingly, at 4 ng
and 8 ng, 80% of embryos completed epiboly and
gastrulation, but they eventually developed defects in
posterior mesoderm structures similar to those seen
following indomethacin treatment. In particular, morphant
embryos also developed disorganized posterior vascula-
ture similar to those seen in indomethacin-treated
embryos, whereby blood cells pooled in the posterior
vessel region (Fig. 7B arrow) compared to uninjected
embryos (Fig. 7A). In addition, staining with pax2.1
(Majumdar et al., 2000) revealed increased posterior
nephric duct size in morphants (Fig. 7G), compared toFig. 7. cox1-MO causes posterior mesoderm defect similar to indomethacin-induce
MO (B) specifically disrupted posterior mesoderm organs at 1 day, including enla
with pax2.1 shows increased pronephric duct size in the posterior region (D). As th
nephric duct size at day 2 (H, arrow) and day 3 (I, arrow), compared to wild-typthe control siblings (Fig. 7D arrow). The increased
staining correlated with the enlarged posterior nephric
duct that persisted at day 2 (Fig. 7H arrow) and day 3
(Fig. 7I arrow). Enlargement of posterior nephric duct
also occurred with lower dose of indomethacin (25 AM),
in which milder vessel defect and enlarged posterior
nephric duct were seen, another evidence that we were
treating the embryos with physiologically relevant dose of
indomethacin.
Injection of higher dose of MOs at 10 ng/embryo led
to gastrulation arrest at around the 40–50% epiboly stage
in over 90% of the injected embryos (Fig. 8A), similar to
the results seen in embryos treated with 50 AM
indomethacin during gastrulation. Co-injecting cox1-MO
with synthetic cox1 RNA, harboring five-point mutations
in the MO binding region, suppressed the gastrulation
arrest and allowed the embryos to progress past the
tailbud stage (Fig. 8B), demonstrating that cox1-MO
specifically binds to endogenous cox1 mRNA and does
not interfere with translation of different transcripts. From
these results, we conclude that functional knockdown ofd phenotype. Compared to uninjected wild-type (A), injection of 8 ng cox1-
rged nephric duct and distended posterior vasculature (B, arrow). Staining
e embryos develop, the increased staining correlates to increase in posterior
e (E, F).
Fig. 8. COX-1 knockdown results in gastrulation defect at high dose.
Injection of 10 ng cox1-MO results in gastrulation arrest at ~50% epiboly
stage (A). Gastrulation arrest defect by cox1-MO can be rescued by co-
injecting synthetic cox1 RNA, mutated in MO-binding site (B). Black bar
indicates the percentage of embryos that survived to tailbud (C). In the
rescue experiments (lane 3, 4), we tested at least 80 embryos from two
independent experiments, while in cox1 RNA injection groups (lane 5, 6),
at least 50 embryos from two independent experiments were analyzed.
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defects and gastrulation arrest similar to that seen with
pharmacologic COX-1 inhibition.Discussion
Limitations in murine model for elucidating COX biology
prompted investigation in zebrafish model system. During
embryogenesis, COX-1 shows specific spatiotemporal
expression in the posterior mesoderm, which localizes to
posterior nephric duct, cloaca, hypochord, and blood vessel.
In mammals, normal endothelial cells and vascular smooth
muscle cells express COX-1 (Hla and Neilson, 1992).
Grosser et al. elegantly demonstrated that COX inhibitors,
indomethacin, suppressed the formation of PGs in live
zebrafish. Indomethacin was a more effective inhibitor of
COX-1-derived PGs, while both indomethacin and NS-398
were effective inhibitors for COX-2. Similar IC50 were
obtained for both inhibitors (Grosser et al., 2002). Treatment
of zebrafish embryos during late segmentation stages with
indomethacin resulted in dramatic defect in posterior
vasculature, in which single, distended blood vessel
remained after 2 days, instead of the blood vessel differ-
entiating into artery and vein. Treatment with NS-398 did not
have any effect on normal vessel formation. We also
observed similar defect in vessel formation with COX-1morpholino treatment, but not to the same degree as that seen
following indomethacin treatment. Since high-dose COX-1
morpholino treatment results in gastrulation arrest, we can
only utilize lower dose of COX-1 to monitor vessel defect,
likely achieving only a partial loss of the gene function.
Indomethacin treatment specifically inhibits COX activity,
since reconstituting PGE2 can suppress vessel defect.
COX-1 is expressed in the developing vasculature and
regulates arterio-venous differentiation. It appears that COX-
1 function is critical for vascular tube formation by
angioblast at around 25 somite stage. At 24 hpf, we observed
the presence of arterial and veinous endothelial cells by both
flk1, flt4, and ephB2 staining, but the boundary between
arterial and veinous structures was completely missing. We
hypothesize that COX-1 regulates proper morphogenesis of
the angioblast during tubulogenesis. However, it is not clear
why there is a strong downregulation of veinous staining,
compared to arterial staining. Perhaps there may be a defect
in veinous differentiation as well as angioblast morpho-
genesis. It would be important to carefully analyze the
cellular changes in the affected angioblasts to understand
how COX-1 functions during tube formation.
In addition to defect in vascular tube formation, COX-1
inhibition also appears to inhibit angiogenesis by sprouting
intersomitic vessel. In mammalian systems, mounting
evidence suggest the role of COX and its products in
angiogenesis. Tsujii et al. showed the antisense oligonucleo-
tide against COX-1 resulted in the inhibition of tubal
formation by HUVECs (Tsujii et al., 1998). Various studies
also indicate that NSAIDs inhibit angiogenesis in vivo
models (Majima et al., 1997), primarily by inhibition of
PGE2 formation. PGE2 upregulates the production of
angiogenic factors (VEGF, bFGF), which are important
for the growth and survival of endothelial cell proliferation
(Iniguez et al., 2003). During the early development, VEGF
production appears to be unaltered in indomethacin-treated
group. It appears that the defect in intersomitic vessel
angiogenesis is due to a primary defect in vascular tube
formation.
In summary, this study opens an exciting area of
investigation focused on dissecting the prostanoid pathway
in zebrafish model system. Prostaglandin biosynthetic
pathway is conserved in zebrafish, therefore the next step
would be to perform functional analysis on downstream
receptor pathways. Since COX enzymes are conserved, it is
reasonable to hypothesize that prostanoid receptor pathways
are also conserved. True to this hypothesis, our analysis
through zebrafish genome database revealed presence of
both EP and FP receptors (YC, LSK, RND, unpublished
observations). Therefore, it would be important to under-
stand what downstream receptor mediates prostaglandin
signaling in formation of vascular tubes. In addition, the
increased risk of cardiovascular defects in patients who
ingest high doses of COX-2 inhibitors (Fitzgerald, 2004)
illustrates the importance of understanding prostaglandin
pathway in regulating cardiovascular homeostasis.
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